ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif. , Sept. 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc.
Read more